Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.
To address the impact of partial reduction of Pten on tumor initiation, we generated PtenshRNA mice, in which PTEN expression was reduced below normal levels in various tissues. PtenshRNA mice frequently developed lymphoid and prostatic hyperplasia, splenomegaly, and sebaceous adenomas. Our observations support the notion that partial reduction of the dose of Pten with shRNA is sufficient to induce neoplastic disease in multiple organ systems.
Shen-Li
Hong
H
Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Koujak
Susan
S
Szablocs
Matthias
M
Parsons
Ramon
R
D000236:Adenoma / Q000201:enzymology / Q000235:genetics; D000311:Adrenal Glands / Q000473:pathology; D000818:Animals; D001921:Brain / Q000033:anatomy & histology / Q000201:enzymology; D004717:Endometrium / Q000473:pathology; D005260:Female; D006965:Hyperplasia; D008206:Lymphatic Diseases / Q000201:enzymology / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental / Q000201:enzymology* / Q000235:genetics; D009929:Organ Size; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis / Q000172:deficiency* / Q000235:genetics*; D010766:Phosphorylation; D011470:Prostatic Hyperplasia / Q000201:enzymology / Q000235:genetics; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000235:genetics; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics; D012626:Sebaceous Gland Neoplasms / Q000201:enzymology / Q000235:genetics
D034741:RNA, Small Interfering; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase